Quednow BB

Experimental Pharmacopsychology and Psychological Addiction Research, Department of Adult Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich 8032, Switzerland.

17 papers · 1 preprint · ORCID

ArticleMDMA

Reply: The consequences of MDMA use are not easily disentangled from other drug use or lifestyle factors.

Quednow BB, Coray RC

Europe PMC2026
ArticleMDMA

Changing Patterns of Recent Substance Use in Emerging Adulthood and Their Associations With Cognitive Functions and Mental Health.

Eggenberger L, Janousch C, Johnson-Ferguson L +6

Europe PMC2026
ArticleDMT

Combined DMT-harmine formulation reduces negative self-referential emotions during social self-evaluation: a randomized placebo-controlled trial in healthy volunteers.

Aicher HD, Dornbierer J, Caflisch L +6

Europe PMC2026
ArticlePsilocybin

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomized [<sup>18</sup>F]FDG-PET study.

Egger K, Bozsak R, Aicher HD +9

Europe PMC2026
ArticleMDMA

Differential alterations in peripheral tryptophan pathways in methamphetamine versus MDMA users are linked to their contrasting psychiatric symptoms.

Bavato F, Steuer A, Jacobsen AM +8

Europe PMC2026
ArticleMDMA

Memory deficits of MDMA users are linked to cortical thinning related to 5-HT receptor densities.

Coray RC, Beliveau V, Zimmermann J +8

Europe PMC2026
ArticleMDMA

Something is not nothing: Hair-tested substance use and cognitive functions in a large community sample of young adults.

Eggenberger L, Janousch C, Johnson-Ferguson L +6

Europe PMC2026
ArticleMDMA

How do substance and polysubstance use trajectories differ by sexual attraction from ages 17 to 24? A community-based longitudinal cohort study in Switzerland.

Janousch C, Vock F, Winter BL +10

Europe PMC2026
PreprintMDMA

Differential alterations in peripheral tryptophan pathways in methamphetamine versus MDMA users are linked to their contrasting psychiatric symptoms

Bavato F, Steuer A, Jacobsen AM +8

Europe PMC2025
ArticleAyahuasca

Examining the pharmacokinetic and pharmacodynamic interaction of N,N-dimethyltryptamine and harmine in healthy volunteers: Α factorial dose-escalation study.

Egger K, Jareño Redondo J, Müller J +13

Europe PMC2025
ArticleAyahuasca

Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial.

Mueller MJ, Aicher HD, Dornbierer DA +16

Europe PMC2024
ArticleMDMA

Words versus Strands: Reliability and Stability of Concordance Rates of Self-Reported and Hair-Analyzed Substance Use of Young Adults over Time.

Janousch C, Eggenberger L, Steinhoff A +9

Europe PMC2025
ArticlePsilocybin

[Psychedelic and dissociative agents in psychiatry: challenges in the treatment].

Jungwirth J, Bavato F, Quednow BB

Europe PMC2024
ArticleDMT

A pilot study of cerebral metabolism and serotonin 5-HT<sub>2A</sub> receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine.

Egger K, Gudmundsen F, Jessen NS +10

Europe PMC2023
ArticleMDMA

Substance use in sexual minority youth: prevalence in an urban cohort.

Vock F, Johnson-Ferguson L, Bechtiger L +7

Europe PMC2023
ArticlePsilocybin

Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.

Cumming P, Scheidegger M, Dornbierer D +3

Europe PMC2021
ArticleKetamine

Novel Psychoactive Substances-Recent Progress on Neuropharmacological Mechanisms of Action for Selected Drugs.

Hassan Z, Bosch OG, Singh D +6

Europe PMC2017
ArticlePsilocybin

Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers.

Quednow BB, Kometer M, Geyer MA +1

Europe PMC2012